While there are now many effective drug treatments for PAH and PH, new molecular pathways of disease offer horizons for novel therapeutic developments that may, alone or in combination with existing, approved medications, alter the process of PH as a disease. This program examines some of the bright lights on the horizon of PH treatment and emerging drug delivery approaches to getting PH medications to their intended site of action. The emergence of these new agents could radically alter the way we think about combination therapy for PAH and other forms of PH.

While there are now many effective drug treatments for PAH and PH, new molecular pathways of disease offer horizons for novel therapeutic developments that may, alone or in combination with existing, approved medications, alter the process of PH as a disease. This program examines some of the bright lights on the horizon of PH treatment and emerging drug delivery approaches to getting PH medications to their intended site of action. The emergence of these new agents could radically alter the way we think about combination therapy for PAH and other forms of PH.

While there are now many effective drug treatments for PAH and PH, new molecular pathways of disease offer horizons for novel therapeutic developments that may, alone or in combination with existing, approved medications, alter the process of PH as a disease. This program examines some of the bright lights on the horizon of PH treatment and emerging drug delivery approaches to getting PH medications to their intended site of action. The emergence of these new agents could radically alter the way we think about combination therapy for PAH and other forms of PH.

While there are now many effective drug treatments for PAH and PH, new molecular pathways of disease offer horizons for novel therapeutic developments that may, alone or in combination with existing, approved medications, alter the process of PH as a disease. This program examines some of the bright lights on the horizon of PH treatment and emerging drug delivery approaches to getting PH medications to their intended site of action. The emergence of these new agents could radically alter the way we think about combination therapy for PAH and other forms of PH.

Duchenne Muscular Dystrophy, or DMD, is considered a rare disease, affecting 1 in 3,500 boy births. But to the patients afflicted-and to the families who love them-it is a painful, everyday experience. Current advances in gene transfer therapy are exciting. Helping clinicians interpret and utilize the outcomes of gene therapy clinical trials is critical to effective treatment and management of DMD, as is the coordination of multidisciplinary teams for the ongoing care of these patients.

Tune in to this live broadcast on overactive bladder! Experts David Staskin, MD, and Roger Dmochowski, MD, discuss evidence-based best practices in the management and treatment of OAB and integrate challenging case studies throughout the broadcast.

Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this activity series employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a series of six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.

This activity focuses on the role of emergency medicine clinicians in the recognition and management of ARIA. This includes an overview of how ARIA may present to the emergency department and what courses of action to treat/manage ARIA may be needed from the hospital care team.

Note that the core activity is supplemented by an

Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this activity series employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a series of six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.

This activity finishes out the series by first providing an abbreviated outline of what has been addressed across activities 1-5 followed by a multidisciplinary discussion of questions and considerations that may impact the team-based execution of discussed strategies.

First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.

First-line treatment for glaucoma is typically pharmacologic and aimed at lowering intraocular pressure, which is the only modifiable risk factor to date. However, successful treatment with traditional topical glaucoma medications may be limited by their well-known barriers of adverse effects and poor patient adherence to drop instillation. Tune in to hear Dr. Qi Cui and Dr. Davinder Grover discuss the novel pharmacological therapies and minimally invasive glaucoma surgery procedures that can lower treatment burden and increase compliance.